September, 22nd – 24 th, 2022


Dear friends and colleagues,

It is our great pleasure to organize the next EORTC CLTG meeting in Madrid, 22-24 September 2022, on the theme “Cutaneous lymphomas: from molecules to PROs”.

We would like to thank the board of the EORTC CTLG for giving us this opportunity. It is a great honor, we are extremely happy and very excited with this task.

The EORTC CLTG Annual Meeting has been a major event for the scientific community all across Europe and it is constantly evolving, becoming more popular, innovative and influential, while maintaining high standards of scientific quality and family atmosphere.

We plan to organize a meeting including everything related to cutaneous lymphomas, from molecules to patient reported outcomes. We would like to have the latest advances in basic and translational research, the latest data originated from PROCLIPI, the latest novelties in treatment. Very importantly, we will include a session for patients at the end of the meeting.

Besides that, we would like to organize a meeting very comfortable for delegates and attendants, plenty of social interaction, plenty of friendship and maybe with some fun. Please, come to Madrid to present your work, your data, your research; come to Madrid to learn, to teach, to enjoy.

We look forward to welcoming you to Madrid in September 2022.


Julia Scarisbrick, EORTC CLTG Chair
PL Ortiz-Romero, Chair of the EORTC CLTG meeting 2022 in Madrid.



Julia Scarisbrick, Chair
Evangelia Papadavid, Secretary
Emmanuella Guenova, Treasurer

Conference Organizing Committee

Pablo L Ortiz Romero
Jose Luis Rodríguez Peralto
Concepción Postigo Llorente
Daniel Falkenhain
Cristina Vico Alonso
Eloy Tarín Vicente
Alba Sánchez Velázquez
Margarita Sánchez-Beato
María S. Rodríguez Pinilla
Marta Rodriguez Moreno
Ruth Alonso

Scientific committee

Chalid Assaf
Martine Bagot
Emilio Berti
Marie Beylot – Barry
Antonio Cozzio
Teresa Estrach
Ricardo Fernández de Misa
Fernando Gallardo
Emmanuella Guenova
Emmilia Hodak
Werner Kempf
Claus-Detlev Klemke
Robert Knobler
Mercedes Morillo

Cristina Muniesa
Jan Nicolay
Pablo Luis Ortiz Romero
Evangelia Papadavid
Ramón Pujol
Pietro Quaglino
Annamari Ranki
Octavio Servitje
Rudolf Stadler
Franz Trautinger
Maarten Vermeer
Sean Whittaker
Rein Willemze



The goal is to offer a comprehensive conference to present new research, share experiences, and discuss new directions or the advancement of knowledge in Cutaneous Lymphomas.

Who attends this meeting 

The conference is designed for international dermatologists, basic scientists, epidemiologists, hematologists, immunologists, oncologists, pathologists, radiation oncologists, and psychologists.
The program committee expects 200-300 attendees. The participation of students and post-doctoral fellows is encouraged through reduced registration fees, oral presentations, and poster sessions.
A session dedicated to patients will be organized on Saturday afternoon in partnership with the newly stablished Spanish Assotiation of Cutaneous Lymphoma Patients.

General Meeting Information

Official Hotel

Only You Atocha
P.º de la Infanta Isabel, 13,
28014 Madrid
Telf. (+34) 914 09 78 76

Official Transfer to Venue

Thursday, 22nd september

12.00 hrs – Transfer Only You Atocha Hotel – Hospital
20.15 hrs – Transfer Hospital – Only You Atocha Hotel

Friday, 23th september

08.00 hrs – Transfer Only You Atocha Hotel – Hospital
20.00 hrs – Transfer Hospital – Only You Atocha Hotel

Saturday, 24th september

08.30 hrs – Transfer Only You Atocha Hotel – Hospital
After Meeting, Transfers Hospital – Only You Atocha Hotel / Airport will be organized (please ask at registration desk for more information).

Name Badges

Participants will receive their badges on site at registration desk. The meeting bagde shoul be worn by all participants at all times during the meeting to ensure Access to the relevant áreas.

This includes the Scientifc Sessions, the coffee-breaks and lunches, the exhibition área and other áreas of the meeting venue as well as the social activities. Only participants wearing their meeting badge will be admitted to the above mentioned áreas and activities.

Covid-19 Requirements

A fase mask  is mandatory in Hospital & Transport (train, Buses, etc) and a responsable use is recommend inside closed public spaces where there are people in transito or staying for a prolonged amount of time.


Our meeting secretariat will be at your disposal at the registration desk anytime during the congress.

Certificates of attendance

All registered delegates will receive a Certificate of Attendance

Presentation Guidelines


The oficial language of the EORTC CLTG 2022 Meeting is English, therefore all types of presentations must be prepared and delivered in English.

Oral Presentations

Each oral presentation has been allocated a time slot of 12 minutes (8 minutes speech and 4 minutes for questions and discussion). Authors are kindly asked to follow the assigned time strictly, the remaining time for the presentation and discussion will be announced and controlled by the Session Chairs.

Presentation Preview Desk

You will assisted in the presentation preview desk by the technical team, who will help you upload your presentation on site. You will also be able to review your presentatrion and verify that it has been transferred correctly.

Your presentation must be uploaded as much in advance as possible, but no later than FOUR HOURS BEFORE the beginning of the respective session. Presentations for an early morning session must be uploaded the day before. When uploading multimedia files, do not forget to double check all your video files and all links to these multimedia that files are functional.

Meeting Code of Conduct

The European Organisation for Research and Treatment of Cancer (EORTC) is committed to providing a safe, secure, collegial and welcoming environment for all participants and attendees at its in-person and to provide for equal opportunity and treatment for all participants and attendees, regardless of actual or perceived gender identify, race, ethnicity, sexual orientation, ability, socioeconomic status, age or religion. All participants, attendees, speakers, exhibitors, satt, contractors, vendors and other service providers, and anyone else present EORTC in-person are expected to abide by this policy. This policy applies to all EORTC CLTG Meeting-related events, including those sponsored by organizations ogher that EORTC but held in conjuntion with EORTC events, in public or private facilities.

Photography, Social Media and Recording Policy

Programe attendees at EORTC CLTG Meeting may use photographs, screenshots and audio/video recordings taken during all Scientific, Oral or Posters presensentation as well as social activities provided that the photographs and recordings are strictly for personal, noncommercial use and are not to be published in any form, EXCEPT when the speaker sor poster presenters explicitly state otherwise at the start of their presentations or by indicating so on their slides and posters through one of two mechanisms:

A camera icon with a red circle and slash on slides or posters indicates that picture taking, audio recording and video recording are not allowed


The words writen “DO NOT POST” written on slides or posters indicate that picture taking, audio recording and video recording are not allowed.

Social Media

EORTC CLTG encourages live tweeting and other social media during programs. Guidelines for the use of social media include:

– Promoting the dedicated program hashtag in your tweets.

– Using tweets as a fórum for discussion and engagement (use of “@” nametags)

– Do not live-tweet presentations or posters until the presentation or poster session has officially opened.

– Be respectful and do not share information of presenting authors who Opt-out of social media, or who use a “non social media” icon in their material.

-Indicate that content should not be shared publicly using a camera icon with a red circle on slides or posters.

-Include the words “DO NOT POST” on slides or posters.

-Do not use digital photographs of slides in social media and avoid posting raw data unless it is already in the public domain.


Insurance, Liability

All participants are reminded that the EORTC CLTG 2022 Meeting Madrid Organisation are not liable for any losses, accidents or damage to persons or private property. Participants are strongly advised to make their own arragements in respect to health, personal and travel insurance in their country of origin.

In case of emergency

In Spain, 112 is the general number for contacting the emergency services

Social Events

Welcome Reception

The welcome reception will be held at the meeting Venue at the Hospital
Thrusday, September 22nd 2022
19:30 – 20:15 hrs

Congress Dinner

Friday, September 23th 2022
21:00-23:30 hrs
NUBEL Restaurant (The Museo Reina Sofía) – Nubel Building
Ronde de Atocha Street, Num 2 (entrance by Patio Nubel)

The opening of the Museo Nacional Centro de Arte Reina Sofía in 1990 meant the creation of a Museum of modern and contemporary Art in Spain of international level.
The Restaurant has an urban and young cuisine that defends the traditional cuisine and updates it with new ingredients and techniques designed by the Arquitect Jean Nouvel.

Visit The Museo Reina Sofia

We will have a private Visist after the Congress Dinner
Friday, September 23th 2022
23:30 hrs

Conference Focus

The conference will present sessions covering all aspects of cutaneous lymphomas including:

  • Pathophysiology, Genomics and Epigenomics, Molecular targets
  • Immunology, Host response, Animal models, Microenvironment
  • Translational Research, diagnostic and prognostic markers
  • Pathology
  • Epidemiology
  • PROCLIPI research
  • New treatments, clinical trials, topical and systemic therapies, combination of treatments, therapeutic strategies
  • Non MF T-cell lymphoma, B cell lymphoma
  • Quality of Life and Patient Reported outcomes.

Program at a glance

  • Thursday, 22 September
  • Friday, 23 September
  • Saturday, 24 September
Hotel Only You Atocha
8:00h – 9:00h
Chairs: J Scarisbrick, E Guenova, E Papadavid
***Closed meeting, only under invitation
9:00h – 10:00h
Breakup meeting UV treatments for cutaneous lymphoma
Chairs: S Whittaker, J Latzka
***Closed meeting, only under invitation
10:00h – 11:00h
Chairs: M Vermeer, S Najidh
***Closed meeting, only under invitation
11:00h – 12:00h
Patch/plaque project
Chairs: J Scarisbrick, P Quaglino. M Bagot, E Hodak
***Closed meeting, only under invitation
12:00h Transfer Only You Atocha Hotel – Hospital
12:45h Lunch at Hospital
13:25h Opening Ceremony
Dra. Carmen Martínez de Pancorbo
Prof. Julia Scarisbrick
Dr. PL Ortiz-Romero

A multi-level analysis of chlormethine: from skin cells to clinical cases
Chair Co-Chair
Pablo L Ortiz-Romero
Hospital 12 de Octubre, Universidad Complutense, Madrid Medical School, Madrid, Spain
Emmanuella Guenova
University of Lausanne,
Lausanne, Switzerland
To summarize the data available regarding the mechanism of action of chlormethine (CL) gel, and discuss its potential use as a combination therapy for patients with mycosis fungoides (MF)
13:30 – 13:35 Opening and welcome
Pablo L Ortiz-Romero
13:35 – 13:50 The skin level: Release, permeation, and pharmacokinetics of chlormethine (CL) gel
Pablo L Ortiz-Romero
13:50 – 14:05 The molecular level: The mode of action of CL gel and impact on T cells
Emmanuella Guenova
14:05 – 14:15 The patient level: An expert interview on how to utilise CL gel in real clinical practice
Emmanuella Guenova, interviewed by Pablo L Ortiz-Romero
14:15 – 14:25 Interactive Q&A session
Emmanuella Guenova and Pablo L Ortiz-Romero, moderated by Pablo L Ortiz-Romero
14:25 – 14:30 Closing remarks
Pablo L Ortiz-Romero

Oral Presentations 01. Biologic insights
Chairs: M Vermeer, M Bagot, J Guitart
14:30h BioIns-O-01 Immunophenotypic identification and characterization of CTCL tumor cells in blood using standardized flow cytometry: A European Multicenter Study
S Najih
Leiden University Medical Center (LUMC), Leiden, The Nederlands
14:42h BioIns-O-02 Targeting immunosuppressive macrophages in the cutaneous T-cell lymphoma microenvironment.
CP Portocarrero
Department of Dermatology and Cutaneous Biology. Thomas Jefferson University, Philadelphia, USA
14:54h BioIns-O-03 Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.
CP Tensen
Leiden University Medical Center (LUMC), Leiden, The Nederlands
15:06h BioIns-O-04 POT1 gene dysfunction in Primary Cutaneous T-cell Lymphoma.
F Bakr
Guys and St Thomas’s NHS Trust, London, UK
15:18h BioIns-O-05 Dual blocking of CD47 and PD-L1 increases innate and adaptive immune responses in CTCL.
C Querfeld
City of Hope Cancer Center and Beckman Research Institute, Duarte, CA, USA
15:30h Coffee Break

Oral Presentations 2. Biologic insights
Chairs: Y kim, JP Merlio. E Guenova
16:00 BioIns-O-06 Single-cell RNA sequencing reveals race-based heterogeneity of malignant T-cells and skin microenvironment in patients with cutaneous T-cell lymphoma.
D Weiner
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, USA
16:12 BioIns-O-07 Mycosis Fungoides: molecular identity revealed by nanostring analysis.
R Alonso Alonso
Department of Pathology, Fundación Jiménez Díaz, Madrid, Spain
16:24 BioIns-O-08 Single-cell RNA sequencing analyses of primary cutaneous B-cell disorders reveal distinct molecular patterns consistent with clinical behavior.
JG Griss
Medical University of Vienna, Vienna
16:36 BioIns-O-09 Risk of progression of early-stage mycosis fungoides from RNA analysis.
V Gargallo Moneva
Service of Dermatology, Hospital del Sureste, Madrid
16:48 BioIns-O-10 Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in leukemic cutaneous T-cell lymphoma patients.
YCT Tsai
Department of Dermatology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Oral Presentations 3. Biologic insights
Chairs: R Willemze, J Choi, F Gallardo
17:00h BioIns-O-11 Combination of JAKi and MAPKi exerts antiangionenic potential in Cutaneous T-cell Lymphoma.
F Karagianni
National Center of Rare Diseases-Cutaneous Lymphoma, Second Department of Dermatology and Venereal Diseases, Attikon University General Hospital, Athens
17:12h BioIns-O-12 Cutaneous Lymphocyte Antigen (CLA) is a potential therapeutic target in Cutaneous T Cell Lymphoma.
S Poglio
BRIC (Bourdeaux Institute of Oncology), UMR1312, INSERM, Univ. Bordeaux, F-33000, Bordeaux, France
17:24h BioIns-O-13 Proliferative tumor infiltrating lymphocytes within microenvironment impact prognosis in cutaneous B-cell lymphomas.
A Pham-Ledard
BRIC (Bourdeaux Institute of Oncology), UMR1312, INSERM, Univ. Bordeaux, F-33000, Bordeaux, France
17:36h BioIns-O-14 Translational research linked to PIMTO-MF clinical.
PL Ortiz-Romero
Department of Dermatology, Hospital Universitario 12 de Octubre, Medical School, Institute i+12, CIBERONC, University Complutense Madrid, Madrid
17:48h BioIns-O-15 CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.
A De Masson
INSERM U976, Sant-Louis Hospital, Paris, France

Oral Presentations 4. Histopathology
Chairs: M Battistella, A Gru, W Kempf
18:00h Hist-O-01 Artificial intelligence-assisted probability scoring for differentiation of early mycosis fungoides and benign inflammatory dermatoses on H&E-stained pathology slides of skin biopsies.
T Doeleman
Leiden University Medical Center (LUMC), Leiden, The Nederlands
18:12h Hist-O-02 Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: an EORTC-CLG/ISCL survey.
P Quaglino
Clinic of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy
18:24h Hist-O-03 Different subtypes of lymphomatoid papulosis are more overlapping than expected – an analysis of published histologic patterns and criteria.
T Fricke
University Medical Center Goettingen, Department of Dermatology, Veneorology and Allergology, Goettingen, Germany
18:36h Hist-O-04 Aggressive cytotoxic dermal lymphomas of the earlobe: a single-institution case series.
J Guitart
Department of Dermatology, Northwestern University, Chicago, USA
18:48h Hist-O-05 Histiocytoid Sweet’s Syndrome in a patient with myelodysplastic syndrome with multilineage dysplasia (MDS-MLD), and monoclonal gammopathy of undetermined significance (MGUS) IgG kappa type.
O Pavlova
Department of Dermatology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
19:00h Poster session 1. Poster walk
Selected authors should be present to explain their posters
BioIns-PO-03 IL32β supports the HLA I expression on tumor skin T lymphocytes as a tumor immune escape mechanism in cutaneous T-cell lymphoma
YT Chang
Department of Dermatology, Centre Hospitalier, Universitaire Vaudois (CHUV), Lausanne, Switzerland
BioIns-PO-5 Unraveling tumor micro-environment by cellular and proteome analyses of suction blister fluid of early-stage mycosis fungoides lesions compared to non-lesional skin over time on chlormethine gel treatment using flow cytometry.
SS Wind
Leiden University Medical Center (LUMC), Leiden, The Nederlands
BioIns-PO-09 Elevated A-to-I RNA editing in leukemic cutaneous T-cell lymphoma.
L Moyal
Department of Dermatology, Rabin Medical Center and Felsenstein Research Center, Tel-Aviv University, Israel
Clin-PO-05 Illness perception of early-stage mycosis fungoides among dermatologists:
a multi-center cross-sectional study
A Barzilai
Department of Dermatology, Sheba Medical Center, Tel Aviv, Israel
20:15h Transfer Hospital – Only You Atocha Hotel
8:00h Transfer Only You Atocha Hotel – Hospital

INDUSTRY SYMPOSIUM: Therakos. Mallinckrodt
Role of ECP Immunomodulation in current treatment strategies for CTCL
Moderator Prof Robert Knobler, Medical University of Vienna, Austria
08:30 – 08:55 ECP in the current International Guidelines & Clinical update
Prof Julia Scarisbrick, University Hospital Birmingham, United Kingdom
08:55 – 09:20 Role of ECP in the management of CTCL – Spanish experience
Prof Pablo Ortiz, Hospital Universitario 12 de Octubre, Madrid, Spain
09:20 – 09:30 Q&A
Guest lecture 1
Prof. Miguel Angel Piris. Fundación Jiménez Díaz, Madrid
Cutaneous Lymphoma Diagnosis: tools and goals
Chair: PL Ortiz-Romero, J Scarisbrick

Miguel A Piris is pathologist, author of more than 470 articles in lymphoma diagnosis and cancer molecular pathogenesis, h-index: 78. He is currently Associate Chief of Pathology at the Fundacion Jimenez Diaz, Madrid, Spain.

Previous positions:
– Chief of Service at the Pathology Department in the Hospital Universitario Marques de Valdecilla, Santander, Spain and Scientific Director at the Research Institute IDIVAL. 2011-2017
– Director of the Molecular Pathology Program at the Spanish National Cancer Centre (CNIO) for 12 years , 1999-2011
– Past-president of the Spanish Society of Pathology and President of the European Association for Haematopathology 2004-2005.

Dr Piris has been the PI in multiple research projects funded by EU. MINECO-Spain and Spanish Association for Cancer Research

Guest lecture 2:
Prof. Manuel Serrano. Institute for Reserach in Biomedicine (IRB), Barcelona.
Cellular senescence and its impotance in cancer therapy
Chair: PL Ortiz-Romero, J Scarisbrick

Manuel Serrano obtained his PhD in 1991, at the University of Madrid (UAM). From 1991 to 1996, Serrano worked as a postdoctoral researcher in the team of David Beach in Cold Spring Harbor Laboratory, NY. Since 1997, Manuel works in Spain, first in Madrid, at the National Center of Biotechnology (CNB) (until 2003) and at the Spanish National Cancer Research Center (CNIO). In 2017, Serrano moved to the Institute for Research in Biomedicine (IRB), in Barcelona.

Manuel Serrano is recognized in the fields of tumor suppression, senescence, aging and reprogramming. In 1993, he reported the discovery of the gene p16. This gene is among the most important anti-cancer genes but also a key inducer and marker of cellular senescence. Serrano pioneered the generation of genetically-modified mice resistant to cancer. Also, the Serrano laboratory demonstrated that cellular reprogramming into pluripotency is possible within tissues in vivo (Advance of the Year 2013, by Nature Medicine). The focus of his laboratory is to apply their knowledge on senescence and reprogramming to treat degenerative diseases and aging.

11:00h Coffee Break

Oral Presentations 05.
Clinical and Pre-clinical studies.
Chair: R Cowan, C Assaf , E Papadavid
11:30h Clin-O-01 Investigating clinical characteristics and outcomes of hypopigmented mycosis fungoides: retrospective review at a single tertiary referral center.
S Talluru
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, USA
11:42h Clin-O-02 Early versus Advanced stage folliculotropic micosis fungoides survival analysis in a reference latinamerican center.
HC Pérez Cely
National Institute of Cancer, Bogotá, Colombia
11:54h PreClin-O-01 Chimerized anti-ICOS 314.8 monoclonal antibodies inhibit tumor cells and regulatory T cells in patients with Sézary syndrome.
F Amatore
Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS, U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
12:06h PreClin-O-02 First xenograft and cell line of primary cutaneous diffuse large B-cell lymphoma, leg type.
JP Merlio
BRIC (Bordeaux Institute of Oncology) UMR1312, INSERM, Univ. Bordeaux and Dermatology Department, Bordeaux University Hospital, Bordeaux, France
12:18h PreClin-O-03 ICOSL: a new diagnostic marker and a new therapeutic target using an ICOS-Fc construct in Sézary syndrome?
J Giustiniani
INSERM U955, Henri-Mondor Hospital, Créteil, France
12:30h PreClin-O-04 Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate, SGN-CD70A, in patient-derived xenograft models.
WA Ai Zhuang
University of California, San Francisco, USA
12:42h PreClin-O-05 Evaluation of the role of different cell populations and immune regulators in Mycosis Fungoides microenvironment.
A Pavlidis
Department of Dermatology and Venereal Diseases, Attikon University General Hospital, National and Kapodistrian University of Athens, Greece
13:00h Lunch

How does targeted therapy affect immune dysfunction in mycosis fungoides and Sézary syndrome?
13:30h – 13:35h Welcome and introduction
Professor Pablo Ortiz-Romero
Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
13:35h – 13:40 The tumour microenvironment in MF and SS
Professor Martine Bagot
Department of Dermatology and Inserm U976 chez Hôpital Saint Louis, Paris, France
13:40 – 13:55h Effect of mogamulizumab ▼ on the tumour microenvironment and anti-tumour immunity
Dr Hélène Moins-Teisserenc
Department of Hematology, Université de Paris, Institut de Recherche Saint-Louis, Paris, France
13:55 – 14:10h Presentation and mechanisms of mogamulizumab-associated rash
Professor Maxime Battistella
Department of Dermatopathology, Hopital Saint Louis, Paris, France
14:10 – 14:20h Case studies
Professor Martine Bagot and Professor Maxime Battistella
14:20 – 14:30h Q&A and close
POTELIGEO® (mogamulizumab) Prescribing Information can be found via the QR code:

▼ This medicine is subject to additional monitoring, which will expedite the detection of new safety information. Healthcare professionals are encouraged to report suspected adverse reactions.
This activity is developed and funded by Kyowa Kirin International PLC – All rights reserved.
Date of preparation: July 2022


Oral Presentations 6.
Preclinical Studies
Chairs: S Whittaker, J Nicolai, R Pujol
14:30h BioIns-O-16 Digital quantitative detection of DNA methylation biomarkers: A helpful tool in the early diagnosis of Sézary syndrome.
WH Zoutman
Department of Dermatology, Leiden University Medical Center (LUMC), Leiden, The Nederlands
14:42h BioIns-O-17 In vivo modelling of Cutaneous T-cell lymphoma: The role of SOCS1.
Y Luo
Department of Dermatology, Leiden University Medical Center (LUMC), Leiden, The Nederlands
14:54h BioIns-O-18 A 9-gene prognostic signature for predicting survival outcome in mycosis fungoides.
S Alberti-Violetti
Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
15:06h BioIns-O-19 Molecular crosstalk between PLCΓ1 and STAT3 in Cutaneous T-Cell Lymphoma.
V Campbell
King’s College London, London, UK
15:18h BioIns-O-20 Transcriptomic landscape of primary cutaneous diffuse large B-cell lymphoma, leg type reveals novel therapeutic clues.
A Gros
CHU and University of Bordeaux, INSERM U1312, Bordeaux, France
15:30h Coffee Break

Oral Presentations 7.
Chair E Hodak, P Quaglino, O Servitje
16:00h Ther-O-01 Lacutamab in patients with advanced mycosis fungoides according to KIR3DL2 expression: Stage 1 results from the TELLOMAK phase 2 trial.
M Bagot
Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris University INSERM U976, Paris, France
16:12h Ther-O-02 The COBALT-LYM Study of CTX130: A Phase 1 Dose Escalation Study of CD70-Targeted Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients with Relapsed/Refractory (R/R) T-Cell Malignancies.
J Zain
Department of Hematology and Hematopoietic Cell Transpantation, City of Hope, Duarte, USA
16:24h Ther-O-03 Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-cell Lymphomas.
E Mou
University of Iowa, Iowa, USA
16:36h Ther-O-04 Dimethyl fumarate (DMF) therapy in CTCL – final results from a clinical phase II study.
JP Nicolay
Department of Dermatology, University Medical Center Mannheim, Mannheim, Germany
16:48h Ther-O-05 Clinical outcomes of single-agent chemotherapy in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma.
D Weiner
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, USA

Oral Presentations 8.
Chair C Querfeld, A Cozzio, R Stadler
17:00h Ther-O-06 Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced CTCL.
M Oymanns
Helios Klinikum Krefeld, Academic Teaching Hospital of the University of Aachen, Krefeld, Germany
17:12h Ther-O-07 Combination Therapy With Chlormethine Gel and Narrow-Band Ultraviolet B for Patients With Mycosis Fungoides: A Case Series.
L Gleason
Department of Dermatology and Cutaneous Biology. Thomas Jefferson University, Philadelphia, USA
17:24h Ther-O-08 Broad-band ultraviolet A combined with narrow-band ultraviolet B: an effective modality for early folliculotropic mycosis fungoides and early mycosis fungoides refractory to narrow-band ultraviolet B.
I Amitay-Laish
Rabin Medical Center, Beilinson Hospital, Kyriat-Ono, Israel
17:36h Ther-O-09 New type of Mogamulizumab induced rash simulating Lupus miliaris disseminatus faciei.
C Mitteldorf
Department of Dermatology, Venereology and Allergology, University Medical Center, Göttingen, Germany
17:48h Ther-O-10 Real-world study of the use of pegylated interferon alfa for treatment of primary cutaneous T-cell lymphomas. An EORTC CLTF study.
K Mitsunaga
Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain

Oral Presentations 9.
Chair R Knobler, L Geskins , R Fernández de Misa
18:00h Ther-O-11 Polatuzumab vedotin in combination with rituximab and bendamustine (Pola-RB) for relapsed primary cutaneous diffuse large B-cell lymphoma.
L Wilms
Helios Klinikum Krefeld, Academic Teaching Hospital of the University of Aachen, Krefeld, Germany
18:12h Ther-O-12 Time to next treatment and safety assessment in Cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin.
G Roccuzzo
Dermatology Clinic, University of Turin, Turin, Italy
18:24h Ther-O-13 The effect of mogamulizumab on the malignant T cell population – A monocentric retrospective analysis.
JG Gosmann
University Clinic of Dermatology, Johanes Wesling Medical Centre, UKRUB, University of Bochum, Minden, Germany
18:36h Ther-O-14 A Post-hoc Analysis of Clinical Trial Data Shows That Prior Phototherapy Does Not Affect Response to Chlormethine Gel in Patients With Mycosis Fungoides.
C Assaf
Department of Dermatology, Helios Klinikum Krefeld, Germany
18:48h Ther-O-15 TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30.
M Gerlach
Tubulis GmbH, Planegg, Germany
19:00h EORTC CLTG General Assembly

Profesors Julia Scarisbrick, Emmanuella Guenova and Evangelia Papadavid

19:30h ISCL Assembly

Chairpersons: Emmila Hodak, Julia Scarisbrick, Larisa Geskin

19:45h Poster session 2. Poster walk
Clin-PO-06 A case series of three male patients with blastic plasmocytoid dendritic
cell neoplasm
A Osmancevic
Department of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden
Clin-PO-11 Estimates of the rate of growth of lymph nodes measured volumetrically
predicts survival in cutaneous T-cell lymphoma (CTCL)
LM Fahmy
Cutaneous Oncology Research Fellow, Columbia University, New York, USA
Ther-PO-22 Intralesional brentuximab vedotin: our experience in the treatment of
CD30+ primary cutaneous T-cell lymphomas
JA Arroyo Andrés
Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
20:00h Transfer Hospital – Hotel Only You Atocha

Nubel Restaurant (The Museo Reina Sofia) – Nubel Building
Ronda de Atocha Street, Num 2 (entrance by Patio Nubel)
(10 minutes walking distance)

23:30h Visit The Museo Reina Sofia

We will have a Visit after the Congress Dinner

8:30h Transfer Only You Atocha Hotel – Hospital

Evidence-based and Targeted Treatment Decisions for Advanced Cutaneous T-cell Lymphoma
9:00h Welcome and Introduction Chalid Assaf, MD, PhD (Chair)
Helios Klinikum Krefeld
Krefeld, Germany
9:05h Targeted Treatment of CTCL:
Which Patient Groups Benefit?
Chalid Assaf, MD, PhD
9:20h RWE in Targeted Treatment of
CTCL: Closing the Gap of Clinical Trials
Evangelia Papadavid, MD, PhD
National and Kapodistrian University of Athens
Athens, Greece
9:35h Optimizing Treatment Strategy for
Advanced CTCL:
Case Study Analyses
Pietro Quaglino, MD
University of Turin Medical School
Turin, Italy
9:50h Audience Q&A All

PROCLIPI and QUALITY OF LIFE Chair: J Scarisbrick, Y Kim, C Jonak
Prognostic Factors in Mycosis Fungoides & Sezary Syndrome: Results from the PROCLIPI Study
10:00h PROCLIPI-O-01 Prognostic Factors in Mycosis Fungoides & Sezary Syndrome: Results from the PROCLIPI Study
J Scarisbrick
Dermatology, University Hospital Birmingham, UK
10:12h PROCLIPI-O-02 What have we learnt about the treatment of advanced stage mycosis fungoides and Sezary syndrome from the PROCLIPI Study?
P Quaglino
Clinic of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy
10:24h QoL-O-01 Update on the development of EORTC/CLTF questionnaires to assess HRQOL in primary cutaneous T-cell and B-cell lymphomas: Phase I
K Molloy
Dermatology, Tallaght University Hospital, Dublin
10:36h QoL-O-02 Mogamulizumab-associated rashes may be related to improved therapeutic response in T-cell lymphomas
A Pileri
Dermatology Unit, IRCCS Policlinico di Sant’ Orsola, Bologna, Italy
10:48h QoL-O-03 Quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas
AEC Schirren
Department of Dermatology, University Medical Center Mannheim, Mannheim, Germany
11:00h Coffee Break

Oral Presentations 10.
Epidemiology and Imaging
Chairs: JA Sanches, T Estrach, M Beylot-Barry
11:30h Epid-O-01 Racial and ethnic factors associated with differences in the receipt of treatments for patients with mycosis fungoides
J Brown-Korsah
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
11:42h Epid-O-02 Lymphomatoid papulosis in pediatric population: preliminary results of a multicenter retrospective cohort study
M Blanchard
Department of Dermatology, CHUV, Lausanne, University of Lausanne, Switzerland
11:54h Img-O-01 Baseline radiographic imaging is useful in identifying risk factors for survival and lymph node progression
PB Allen
Winship Cancer Institute of Emory University, Atlanta, USA
12:06h Img-O-02 Lymph node infiltration in mycosis fungoides and Sézary syndrome: ultrasound features descriptive study
V Gonzalez
Radiology Department, Hospital 12 de Octubre, Madrid, Spain
12:18h LateBr-O-01 CD8+T lymphocytes in hypopigmented mycosis fungoides malignant cells or reactive clone?
S Cao
Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA
12:30h Meeting Clousure J Scarisbrick, PL Ortiz-Romero

13:00h Simposio para pacientes Patient’s symposium Chair: Susan Thornton, PL Ortiz-Romero, Almudena Montejo Presentation PL Ortiz-Romero

Taller EN VIVO. Maquillaje terapéutico. Una herramienta fundamental para restaurar la autoestima y la calidad de vida de los pacientes Therapeutic Makeup: A fundamental tool to restores self-esteem and quality of life to patients. Live Makeup
Leonor Prieto Cabezas, Scientific Director Loreal Cosmética Activa Spain Expert in corrective and therapeutic makeup
14:05 Lunch

14:25h Asociación Española de Pacientes con Linfoma Cutáneo (AELIC) Spanish Association of Patients with Cutaneous Lymphoma (AELIC)
Susana Díaz Guirado, Joaquín Díez, Almudena Montejo
14:35h Grupo Español de Linfoma Cutáneo Spanish Group of Cutaneous Lymphoma
Cristina Muniesa
14:40h Micosis fungoide y síndrome de Sézary para pacientes Mycosis fungoides and Sézary Syndrome for patients
Mercedes Morillo
14:50h Linfoma anaplástico CD30+ y Papulosis linfomatoide para pacientes Anaplastic CD30+ large cell lymphoma and lymphomatoid papulosis for patients
Daniel Falkenhain
15:00h Linfomas primarios cutáneos de células B para pacientes Primary cutaneous B-cell lymphomas for patients
Concepción Postigo
15:10h Calidad de vida de pacientes con micosis fungoide. Estudio MICADOS Quality of life of patients with mycosis fungoides. MICADOS STUDY
M Mar Onteniente
15:20h Presentación del film «Más allá de la piel» (If you want to see the video, click here)
Film presentation
Marcos Martínez. AEAL.
16:20h Cierre del simposio Close remarks & Clousure Meeting
Susan Thornton, Almudena Montejo, PL Ortiz-Romero